



10/668,920  
expanding structure searches(a)-(c)



chain nodes :

11 12 13 19 20 21 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 22 23 24 25 26 27 28 29 30 31  
32 33

chain bonds :

2-21 9-12 11-12 12-13 14-21 15-20 16-26 17-34 18-19 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-18 15-16 16-17 17-18  
22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31 31-32 32-33

exact/norm bonds :

11-12 12-13 14-15 14-18 14-21 15-16 15-20 16-17 17-18 17-34 18-19

exact bonds :



2-21 9-12 16-26 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 22-23 22-27 23-24 24-25 25-26  
26-27 28-29 28-33 29-30 30-31 31-32 32-33

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS  
12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS  
21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom  
31:Atom 32:Atom 33:Atom 34:CLASS



chain nodes :

6 7 9 16 19 20 21 24 26 27

ring nodes :

1 2 3 4 5 10 11 12 13 14 15

chain bonds :

1-9 2-7 3-26 3-27 4-24 5-6 9-16 11-16 19-20 20-21

ring bonds :

1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-2 1-5 1-9 2-3 2-7 3-4 3-26 3-27 4-5 4-24 5-6 9-16 19-20 20-21

exact bonds :

11-16

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15



G1:C,O,S

G2:Cy,Ak

G3:H,Cy,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 10:Atom 11:Atom  
 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS  
 24:CLASS 26:CLASS 27:CLASS



chain nodes :

6 7 9 16 20 22 23 29 30 31

ring nodes :

1 2 3 4 5 10 11 12 13 14 15 25 26 27 28

chain bonds :

1-9 2-7 3-22 3-23 4-20 5-6 9-16 11-16 29-30 30-31

ring bonds :

1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15 14-25 15-28 25-26  
26-27 27-28

exact/norm bonds :

1-2 1-5 1-9 2-3 2-7 3-4 3-22 3-23 4-5 4-20 5-6 9-16 29-30 30-31

exact bonds :

11-16

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15 14-25 15-28 25-26 26-27 27-28



G1:C,O,S

G2:Cy,Ak

G3:H,Cy,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 20:CLASS 22:CLASS 23:CLASS 25:CLASS  
26:Atom 27:Atom 28:Atom 29:CLASS 30:CLASS 31:CLASS 32:CLASS



chain nodes :  
 6 7 10 12 13 15 16 17 18 19  
 ring nodes :  
 1 2 3 4 5  
 chain bonds :  
 1-15 2-7 3-12 3-13 4-10 5-6 15-16 16-17 17-18 17-19  
 ring bonds :  
 1-2 1-5 2-3 3-4 4-5  
 exact/norm bonds :  
 1-2 1-5 1-15 2-3 2-7 3-4 3-12 3-13 4-5 4-10 5-6 15-16 16-17 17-18 17-19



G1:C,O,S

G2:CY,Ak

G3:H,CY,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 10:CLASS 12:CLASS 13:CLASS  
 15:CLASS 16:Atom 17:CLASS 18:CLASS 19:CLASS



```

chain nodes :
 6 7 10 12 13 15 16 17 18 19 20 21
ring nodes :
 1 2 3 4 5
chain bonds :
 1-18 2-7 3-12 3-13 4-10 5-6 15-17 15-16 15-21 18-19 19-20 20-21
ring bonds :
 1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
 1-2 1-5 1-18 2-3 2-7 3-4 3-12 3-13 4-5 4-10 5-6 15-17 15-16 18-19 19-20
 20-21
exact bonds :
 15-21

```

G1:C,O,S

G2:Cy,Ak

G3:H,Cy,Ak

```

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 10:CLASS 12:CLASS 13:CLASS
 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:CLASS

```

10/668,920 5/27/05

FILE 'HOME' ENTERED AT 19:23:05 ON 24 MAY 2005

=> fil caplus  
COST IN U.S. DOLLARS  
  
FULL ESTIMATED COST

4 MAY 2005  
USPATFULL

SINCE FILE TOTAL  
ENTRY SESSION  
0.21 0.21

FILE 'CAPLUS' ENTERED AT 19:23:12 ON 24 MAY 2005 *reprint*  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

+ trifluoroacetate(salt)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2005 VOL 142 ISS 22  
FILE LAST UPDATED: 23 May 2005 (20050523/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE 'USPATFULL' ENTERED AT 19:23:23 ON 24 MAY 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 May 2005 (20050524/PD)  
FILE LAST UPDATED: 24 May 2005 (20050524/ED)  
HIGHEST GRANTED PATENT NUMBER: US6898801  
HIGHEST APPLICATION PUBLICATION NUMBER: US2005108799  
CA INDEXING IS CURRENT THROUGH 24 May 2005 (20050524/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 May 2005 (20050524/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2005

```
>>> USPAT2 is now available. USPATFULL contains full text of the
>>> original, i.e., the earliest published granted patents or
>>> applications. USPAT2 contains full text of the latest US
>>> publications, starting in 2001, for the inventions covered in
>>> USPATFULL. A USPATFULL record contains not only the original
>>> published document but also a list of any subsequent
>>> publications. The publication number, patent kind code, and
>>> publication date for all the US publications for an invention
>>> are displayed in the PI (Patent Information) field of USPATFULL
>>> records and may be searched in standard search fields, e.g., /PN,
>>> /PK, etc.
```

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>>  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

'BI,IT,ST,CC' IS DEFAULT SEARCH FIELD FOR 'USPATFULL' FILE

=> s naphthalenecarboximidamide and trifluoroacetate  
9 NAPHTHALENECARBOXIMIDAMIDE/BI  
3 NAPHTHALENECARBOXIMIDAMIDE/IT  
3 NAPHTHALENECARBOXIMIDAMIDES/IT  
6 NAPHTHALENECARBOXIMIDAMIDE/IT  
((NAPHTHALENECARBOXIMIDAMIDE OR NAPHTHALENECARBOXIMIDAMIDES)/I  
T)  
6 NAPHTHALENECARBOXIMIDAMIDE/ST  
0 NAPHTHALENECARBOXIMIDAMIDE/CC  
13271 TRIFLUOROACETATE/BI  
809 TRIFLUOROACETATES/BI  
13780 TRIFLUOROACETATE/BI  
((TRIFLUOROACETATE OR TRIFLUOROACETATES)/BI)  
1340 TRIFLUOROACETATE/IT  
10 TRIFLUOROACETATES/IT  
1344 TRIFLUOROACETATE/IT  
((TRIFLUOROACETATE OR TRIFLUOROACETATES)/IT)  
80 TRIFLUOROACETATE/ST  
0 TRIFLUOROACETATE/CC  
L1 6 NAPHTHALENECARBOXIMIDAMIDE/BI, IT, ST, CC AND TRIFLUOROACETATE/BI, I  
T, ST, CC

=> d L1 ibib

L1 ANSWER 1 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2004:159269 USPATFULL  
TITLE: Imidazolidinedione analogs useful as anticoagulants and antiplatelets  
INVENTOR(S): Arnaiz, Damian O., Hercules, CA, UNITED STATES  
Chou, Yuo-Ling, Lafayette, CA, UNITED STATES  
Griedel, Brian D., El Cerrito, CA, UNITED STATES  
Mohan, Raju, Encinitas, CA, UNITED STATES  
Shaw, Kenneth J., Brookside, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin, GERMANY, FEDERAL REPUBLIC OF, D-13342 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122073	A1	20040624
APPLICATION INFO.:	US 2003-668920	A1	20030923 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-413067P	20020924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BERLEX BIOSCIENCES, PATENT DEPARTMENT, 2600 HILLTOP DRIVE, P.O. BOX 4099, RICHMOND, CA, 94804-0099	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1558	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L1 ibib 2-6

L1 ANSWER 2 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2003:6982 USPATFULL  
TITLE: Naphthamidine urokinase inhibitors  
INVENTOR(S): Bruncko, Milan, 13317 Heiden Cir., Lake Bluff, IL,  
United States 60044  
McClellan, William J., 1212 N. Sheridan Rd., Waukegan,  
IL, United States 60085

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6504031	B1	20030107
APPLICATION INFO.:	US 2000-557792		20000425 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-236254, filed on 25 Jan 1999, now patented, Pat. No. US 6284796 Continuation-in-part of Ser. No. US 1998-129989, filed on 6 Aug 1998, now patented, Pat. No. US 6258822		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kumar, Shailendra		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	2920		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L1 ANSWER 3 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2002:332745 USPATFULL  
TITLE: Naphthamidine urokinase inhibitors  
INVENTOR(S): Bruncko, Milan, Lake Bluff, IL, United States  
Dalton, Christopher Robin, Mundelein, IL, United States  
Giranda, Vincent Louis, Gurnee, IL, United States  
Gong, Jianchun, Gurnee, IL, United States  
McClellan, Willian J., Waukegan, IL, United States  
Nienaber, Vicki L., Gurnee, IL, United States  
Rockway, Todd Warren, Grayslake, IL, United States  
Sauer, Daryl Richard, Trevor, WI, United States  
Weitzberg, Moshe, Highland Park, IL, United States  
Abbott Laboratories, Abbott Park, IL, United States  
PATENT ASSIGNEE(S): (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495562	B1	20021217
APPLICATION INFO.:	US 2001-842382		20010425 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-199395P	20000425 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davis, Zinna Northington	
LEGAL REPRESENTATIVE:	Steele, Gregory W., Donner, B. Gregory	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3220	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 4 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2001:224157 USPATFULL  
TITLE: Urokinase inhibitors  
INVENTOR(S): Steele, Andrew W., Novi, MI, United States  
McClellan, William J., Waukegan, IL, United States  
Rockway, Todd W., Grayslake, IL, United States  
Stewart, Kent D., Gurnee, IL, United States  
Weitzberg, Moshe, Highland Park, IL, United States  
Wendt, Michael D., Vernon Hills, IL, United States  
Nienaber, Vicki L., Gurnee, IL, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001049374	A1	20011206
APPLICATION INFO.:	US 2001-850826	A1	20010508 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-129989, filed on 6 Aug 1998, GRANTED, Pat. No. US 6258822		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-54982P	19970806 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven F. Weinstock, Abbott Laboratories, Department 377/ AP6D-2, 100 Abbott Park Road, Abbott Park, IL, 60064-6050	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7946	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 5 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2001:148003 USPATFULL  
TITLE: Urokinkase inhibitors  
INVENTOR(S): Geyer, Andrew G., Chicago, IL, United States  
McClellan, William J., Waukegan, IL, United States  
Rockway, Todd W., Grayslake, IL, United States  
Stewart, Kent D., Gurnee, IL, United States  
Weitzberg, Moshe, Highland Park, IL, United States  
Wendt, Michael D., Deerfield, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284796	B1	20010904
APPLICATION INFO.:	US 1999-236254		19990125 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-129989, filed on 6 Aug 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kumar, Shailendra		
LEGAL REPRESENTATIVE:	Donner, B. Gregory, Steele, Gregory W.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	9202		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L1 ANSWER 6 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2001:107904 USPATFULL  
TITLE: Urokinase inhibitors  
INVENTOR(S): Geyer, Andrew G., Chicago, IL, United States  
McClellan, William J., Waukegan, IL, United States

PATENT ASSIGNEE(S): Rockway, Todd W., Grayslake, IL, United States  
Stewart, Kent D., Gurnee, IL, United States  
Weitzberg, Moshe, Highland Park, IL, United States  
Wendt, Michael D., North Chicago, IL, United States  
Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258822	B1	20010710
APPLICATION INFO.:	US 1998-129989		19980806 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-54982P	19970806 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Donner, B. Gregory, Steele, Gregory W.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7440	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> fil caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	14.16	14.82

FILE 'CAPLUS' ENTERED AT 19:26:48 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2005 VOL 142 ISS 22  
FILE LAST UPDATED: 23 May 2005 (20050523/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s naphthalenecarboximidamide and trifluoroacetate  
22 NAPHTHALENECARBOXIMIDAMIDE  
4 NAPHTHALENECARBOXIMIDAMIDES  
22 NAPHTHALENECARBOXIMIDAMIDE  
(NAPHTHALENECARBOXIMIDAMIDE OR NAPHTHALENECARBOXIMIDAMIDES)  
8250 TRIFLUOROACETATE  
805 TRIFLUOROACETATES  
8611 TRIFLUOROACETATE  
(TRIFLUOROACETATE OR TRIFLUOROACETATES)

L2

3 NAPHTHALENECARBOXIMIDAMIDE AND TRIFLUOROACETATE

=> d L2 1-3 ibib

L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:960658 CAPLUS  
DOCUMENT NUMBER: 138:24650  
TITLE: Preparation of (isoquinolinylcyclopropyl)naphthamidine urokinase inhibitors  
INVENTOR(S): Bruncko, Milan; Dalton, Christopher Robin; Giranda, Vincent Louis; Gong, Jianchun; McClellan, William J.; Nienaber, Vicki L.; Rockway, Todd Warren; Sauer, Daryl Richard; Weitzberg, Moshe  
PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: U.S., 36 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
US 6495562	B1	20021217	US 2001-842382	20010425
PRIORITY APPLN. INFO.:			US 2000-199395P	P 20000425
OTHER SOURCE(S):	MARPAT	138:24650		
REFERENCE COUNT:	28	THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:645690 CAPLUS  
DOCUMENT NUMBER: 135:210841  
TITLE: Preparation of naphthalenecarboximidamides as urokinase inhibitors  
INVENTOR(S): Geyer, Andrew G.; McClellan, William J.; Rockway, Todd W.; Stewart, Kent D.; Weitzberg, Moshe; Wendt, Michael D.  
PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: U.S., 91 pp., Cont.-in-part of U.S. 6,258,822.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
US 6284796	B1	20010904	US 1999-236254	19990125
US 6258822	B1	20010710	US 1998-129989	19980806
US 6504031	B1	20030107	US 2000-557792	20000425
PRIORITY APPLN. INFO.:			US 1998-129989	A2 19980806
			US 1997-54982P	P 19970806
			US 1999-236254	A2 19990125
OTHER SOURCE(S):	MARPAT	135:210841		
REFERENCE COUNT:	23	THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1999:96205 CAPLUS  
DOCUMENT NUMBER: 130:153476  
TITLE: Preparation of naphthalenecarboximidamides as urokinase inhibitors  
INVENTOR(S): Geyer, Andrew G.; McClellan, William J.; Rockway, Todd

W.; Stewart, Kent D.; Weitzberg, Moshe; Wendt, Michael  
D.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905096	A2	19990204	WO 1998-US15386	19980724
WO 9905096	A3	19990603		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9806594	A	19990127	ZA 1998-6594	19980723
CA 2294300	AA	19990204	CA 1998-2294300	19980724
AU 9885874	A1	19990216	AU 1998-85874	19980724
EP 1000018	A2	20000517	EP 1998-937082	19980724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
JP 2002512636	T2	20020423	JP 1999-510121	19980724
BR 9811099	A	20020514	BR 1998-11099	19980724
BG 103981	A	20001130	BG 1999-103981	19991210
MX 9911868	A	20000531	MX 1999-11868	19991216
NO 9906578	A	20000125	NO 1999-6578	19991230
PRIORITY APPLN. INFO.:			US 1997-901040	A 19970725
			WO 1998-US15386	W 19980724

OTHER SOURCE(S): MARPAT 130:153476

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

7.98

22.80

STN INTERNATIONAL LOGOFF AT 19:28:04 ON 24 MAY 2005

5/24/05 10/668,920

FILE 'HOME' ENTERED AT 18:54:59 ON 24 MAY 2005

=> fil caplus  
COST IN U.S. DOLLARS

**FULL ESTIMATED COST**

FILE 'CAPLUS' ENTERED AT 18:55:14 ON 24 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP.USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

ETTE COVERS 1907 - 24 May 2005 VOL 142 TSS 22

FILE COVERS 1907-21 May 2005 VOL 112 ISS 1  
FILE LAST UPDATED: 23 May 2005 (20050523/ED)

New CAS Information Use Policies. enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s pd313049/cn

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L2 0 L1

=> fil caplus  
COST IN U.S. DOLLARS  
  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.45	6.14

FILE 'CAPLUS' ENTERED AT 18:55:46 ON 24 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2005 VOL 142 ISS 22  
FILE LAST UPDATED: 23 May 2005 (20050523/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s "pd 313049"
    175994 "PD"
    2126 "PDS"
    177747 "PD"
        ("PD" OR "PDS")
    2 "313049"
L3      1 "PD 313049"
        ("PD"(W) "313049")
```

```
=> d L3
```

```
L3  ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN  2002:869482 CAPLUS
DN  137:365551
TI  Direct measurement of coagulation factor VIIa activity in plasma and
    application to screening of Factor VIIa inhibitors
IN  Chi, Liguo; Leadley, Robert Joseph, Jr.; Peng, Yun-Wen
PA  USA
SO  U.S. Pat. Appl. Publ., 14 pp.
    CODEN: USXXCO
DT  Patent
LA  English
```

```
FAN.CNT 1
    PATENT NO.          KIND     DATE      APPLICATION NO.      DATE
    -----  -----  -----  -----
PI  US 2002168700      A1    20021114   US 2002-141396   20020508
    US 6773896         B2    20040810
    EP 1260817         A2    20021127   EP 2002-9326    20020502
    EP 1260817         A3    20021218
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
        CA 2385212       AA    20021108   CA 2002-2385212  20020506
        JP 2002360297    A2    20021217   JP 2002-131432  20020507
PRAI US 2001-289539P    P    20010508
```

```
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
=> s us20020168700/pn
L4          1 US20020168700/PN
            (US2002168700/PN)
```

```
=> d
```

```
L4  ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN  2002:869482 CAPLUS
DN  137:365551
TI  Direct measurement of coagulation factor VIIa activity in plasma and
    application to screening of Factor VIIa inhibitors
IN  Chi, Liguo; Leadley, Robert Joseph, Jr.; Peng, Yun-Wen
PA  USA
```

SO U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002168700	A1	20021114	US 2002-141396	20020508 <--
	US 6773896	B2	20040810		
	EP 1260817	A2	20021127	EP 2002-9326	20020502
	EP 1260817	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2385212	AA	20021108	CA 2002-2385212	20020506
	JP 2002360297	A2	20021217	JP 2002-131432	20020507
PRAI	US 2001-289539P	P	20010508		
RE.CNT 40	THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> select L4 1 rn

E1 THROUGH E10 ASSIGNED

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.30	15.44

FILE 'REGISTRY' ENTERED AT 18:57:45 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6  
DICTIONARY FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>


=> s e1-e10

1 65312-43-8/BI  
     (65312-43-8/RN)  
 1 100-01-6/BI  
     (100-01-6/RN)  
 1 10043-52-4/BI  
     (10043-52-4/RN)  
 1 183305-24-0/BI  
     (183305-24-0/RN)  
 1 184770-78-3/BI  
     (184770-78-3/RN)  
 1 475090-17-6/BI  
     (475090-17-6/RN)  
 1 475090-18-7/BI  
     (475090-18-7/RN)  
 1 75-05-8/BI  
     (75-05-8/RN)  
 1 77-86-1/BI  
     (77-86-1/RN)  
 1 9035-58-9/BI  
     (9035-58-9/RN)  
 L5 10 (65312-43-8/BI OR 100-01-6/BI OR 10043-52-4/BI OR 183305-24-0/BI  
       OR 184770-78-3/BI OR 475090-17-6/BI OR 475090-18-7/BI OR 75-05-  
       8/BI OR 77-86-1/BI OR 9035-58-9/BI)

=> d L5 1-10

L5 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **475090-18-7** REGISTRY  
 ED Entered STN: 04 Dec 2002  
 CN 2-Naphthalenecarboximidamide, 7-[(4R)-4-(4-aminophenyl)-3-[(3-  
       aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]- (9CI)  
       (CA INDEX NAME)  
 OTHER NAMES:  
 CN PD 313049  
 FS STEREOSEARCH  
 MF C29 H28 N6 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 475090-17-6 REGISTRY  
 ED Entered STN: 04 Dec 2002  
 CN Benzoic acid, 2-[(6-[3-(aminoiminomethyl)phenoxy]-3,5-difluoro-4-[(1-methyl-3-phenylpropyl)amino]-2-pyridinyl]oxy]-5-(dimethylamino)-4-methyl- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN PD 254751  
 FS 3D CONCORD  
 MF C32 H33 F2 N5 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 184770-78-3 REGISTRY  
 ED Entered STN: 08 Jan 1997  
 CN Benzenecarboximidic acid, 4-[(2S)-3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-, hydrazide (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenecarboximidic acid, 4-[3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-, hydrazide, (S)-  
 OTHER NAMES:  
 CN CI 1028  
 CN LB 30057  
 CN PD 172524  
 FS STEREOSEARCH  
 MF C26 H31 N5 O3 S  
 CI COM  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, IPA, PROUSDDR, SYNTHLINE, USPAT2, USPATFULL


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19 REFERENCES IN FILE CA (1907 TO DATE)  
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 183305-24-0 REGISTRY  
ED Entered STN: 22 Nov 1996  
CN Glycine, N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methyl- (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN CI 1031  
CN Fidexaban  
CN ZK 807834  
FS 3D CONCORD  
MF C25 H24 F2 N6 O5  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, EMBASE, IMSDRUGNEWS,  
IMSRESEARCH, IPA, PHAR, PROUSDDR, SYNTHLINE, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

21 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **65312-43-8** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Blood-coagulation factor VIIa (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Activated blood coagulation factor VII  
CN Blood-coagulation factor VII, activated  
CN Coagulation factor VIIa  
CN E.C. 3.4.21.21  
CN Factor VIIa  
MF Unspecified  
CI MAN  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CAPLUS, CBNB, CHEMCATS, CIN, DIOGENES, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1419 REFERENCES IN FILE CA (1907 TO DATE)  
194 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1423 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **10043-52-4** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Calcium chloride (CaCl<sub>2</sub>) (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Calcium chloride (8CI)  
OTHER NAMES:  
CN Bovikalc  
CN Calcium dichloride  
CN Calcium(2+) chloride  
CN Calcosan  
CN Calmate R  
CN Calol  
CN CalPlus  
CN Calzina oral  
CN Chrysoxel C 4  
CN Daraccel  
CN Dowflake  
CN Intergravin-orales  
CN Liquidow  
CN Peladow  
CN Stopit  
CN U-Ramin MC  
DR 139468-93-2  
MF Ca Cl<sub>2</sub>  
CI COM  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM\*, DIOGENES, DIPPR\*, DRUG\*, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PDLCOM\*, PIRA, PROMT, RTECS\*, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU, VTB

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

C1-Ca-C1

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

38763 REFERENCES IN FILE CA (1907 TO DATE)  
278 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
38802 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **9035-58-9** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Blood-coagulation factor III (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Cephaloplastin  
CN Coagulin  
CN Coagulin (enzyme)  
CN Excel  
CN Excel S  
CN Fibrolet  
CN IL-PT HS  
CN Neoplastin  
CN Procoagulant tissue factor  
CN Thrombokinin  
CN Thromboplastin  
CN Thromboplastin C  
CN Thromboplastin FS  
CN Thromborel  
CN Tissue factor (blood-coagulation)  
CN Tissue thromboplastin  
CN Trombostop  
CN Zymoplastic substance  
DR 9023-20-5  
MF Unspecified  
CI COM, MAN  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CABAB, CANCERLIT, CAPLUS, CHEMCATS, CHEMLIST, CIN, DDFU, DIOGENES,  
DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, PROMT,  
TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

3664 REFERENCES IN FILE CA (1907 TO DATE)  
193 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
3672 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **100-01-6** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Benzenamine, 4-nitro- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Aniline, p-nitro- (8CI)  
OTHER NAMES:  
CN 1-Amino-4-nitrobenzene  
CN 4-Amino-1-nitrobenzene  
CN 4-Aminonitrobenzene  
CN 4-Nitro-1-aminobenzene  
CN 4-Nitroaniline

CN 4-Nitrobenzenamine  
 CN 4-Nitrophenylamine  
 CN Azoamine Red Zh  
 CN C.I. 37035  
 CN C.I. Azoic Diazo Component 37  
 CN C.I. Developer 17  
 CN Developer P  
 CN Devol Red GG  
 CN Fast Red 2G Base  
 CN Fast Red Base 2J  
 CN Fast Red Base GG  
 CN Fast Red GG Base  
 CN Fast Red MP Base  
 CN Fast Red P Base  
 CN Naphtoelan Red GG Base  
 CN Nitrazol CF extra  
 CN NSC 9797  
 CN p-Aminonitrobenzene  
 CN p-Nitraniline  
 CN p-Nitroaniline  
 CN p-Nitrophenylamine  
 CN PNA  
 CN Red 2G Base  
 CN Shinnippon Fast Red GG Base  
 FS 3D CONCORD  
 MF C6 H6 N2 O2  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
     BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,  
     CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM\*, DIPPR\*,  
     EMBASE, GMELIN\*, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,  
     MRCK\*, NIOSHTIC, PDLCOM\*, PIRA, PROMT, PS, RTECS\*, SPECINFO, SYNTHLINE,  
     TOXCENTER, ULIDAT, USPAT2, USPATFULL, VTB  
     (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
     (\*\*Enter CHEMLIST File for up-to-date regulatory information)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9873 REFERENCES IN FILE CA (1907 TO DATE)  
 236 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 9885 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 77-86-1 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (8CI, 9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 2-Amino-1,3-dihydroxy-2-(hydroxymethyl)propane  
 CN 2-Amino-2-(hydroxymethyl)propane-1,3-diol  
 CN 2-Amino-2-hydroxymethylpropan-1,3-diol  
 CN 2-Amino-2-methylol-1,3-propanediol  
 CN Addex-Tham  
 CN Aminotri(hydroxymethyl)methane


CN Aminotrimethylolmethane  
 CN Aminotris(hydroxymethyl)methane  
 CN Methanamine, 1,1,1-tris(hydroxymethyl)-  
 CN NSC 103026  
 CN NSC 6365  
 CN NSC 65434  
 CN Pehanorm  
 CN Sarkosyl  
 CN Talatrol  
 CN TAM  
 CN TAM (buffering agent)  
 CN THAM  
 CN Tri Amino  
 CN Tri(hydroxymethyl)methylamine  
 CN Trigmo base  
 CN Triladyl  
 CN Trimethylolaminomethane  
 CN Tris  
 CN Tris (buffering agent)  
 CN Tris Amino  
 CN Tris Amino Crystal  
 CN Tris buffer  
 CN Tris(hydroxymethyl)aminomethane  
 CN Tris(hydroxymethyl)methanamine  
 CN Tris(hydroxymethyl)methylamine  
 CN Tris(methylolamino)methane  
 CN Tris-steril  
 CN Trisamin  
 CN Trisamine  
 CN Trisaminol  
 CN Trispuffer  
 CN Trizma  
 CN Trometamol  
 CN Trometamole  
 CN Tromethamine  
 CN Tromethane  
 CN Tromethanmin  
 CN Tutofusin tris  
 FS 3D CONCORD  
 DR 25149-07-9, 119320-15-9, 68755-45-3, 83147-39-1, 108195-86-4  
 MF C4 H11 N O3  
 CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
     BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,  
     CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,  
     DETERM\*, DIOGENES, DRUGU, EMBASE, GMELIN\*, HODOC\*, HSDB\*, IFICDB,  
     IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PATDPASPC,  
     PIRA, PROMT, PS, RTECS\*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL,  
     VETU  
     (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*, WHO  
     (\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5290 REFERENCES IN FILE CA (1907 TO DATE)  
351 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
5296 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
71 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 75-05-8 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Acetonitrile (8CI, 9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Acetonitrile cluster  
CN Cyanomethane  
CN Ethanenitrile  
CN Ethyl nitrile  
CN Methane, cyano-  
CN Methanecarbonitrile  
CN Methyl cyanide  
CN Methyl cyanide (MeCN)  
CN NSC 7593  
FS 3D CONCORD  
DR 54841-72-4  
MF C2 H3 N  
CI COM  
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,  
CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM\*,  
DIPPR\*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2,  
GMELIN\*, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*,  
MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM\*, PIRA, PROMT, PS, RTECS\*,  
SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB  
(\*File contains numerically searchable property data)  
Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

33258 REFERENCES IN FILE CA (1907 TO DATE)  
777 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
33318 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.26	34.70

FILE 'REGISTRY' ENTERED AT 18:59:04 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6

DICTIONARY FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> STR 475090-18-7

:END

L6 STRUCTURE CREATED

=> S L6 FAM SAM

SAMPLE SEARCH INITIATED 18:59:08 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7 TO 298  
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA FAM SAM L6

=>

=>

NO ANSWERS WERE FOUND

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	35.13

FILE 'REGISTRY' ENTERED AT 18:59:33 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6  
DICTIONARY FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> S 475090-18-7/RN

L8 1 475090-18-7/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=> D L8 RN CCN 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y  
THE ESTIMATED COST FOR THIS REQUEST IS 1.84 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **475090-18-7** REGISTRY  
CN 2-Naphthalenecarboximidamide, 7-[(4R)-4-(4-aminophenyl)-3-[(3-aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN PD 313049

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=>

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
----------------------	------------	-------

FULL ESTIMATED COST

ENTRY SESSION  
2.70 37.83

FILE 'REGISTRY' ENTERED AT 19:00:48 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6  
DICTIONARY FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> STR 475090-18-7

:END

L9 STRUCTURE CREATED

=> S L9 FAM FUL

FULL SEARCH INITIATED 19:00:52 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 137 TO ITERATE

100.0% PROCESSED 137 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01


L10 3 SEA FAM FUL L9

=>

=> D SCAN

L10 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Naphthalenecarboximidamide, 7-[(4R)-4-(4-aminophenyl)-3-[(3-  
aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]- (9CI)  
MF C29 H28 N6 O2


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3


L10 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Naphthalenecarboximidamide, 7-[[4-(4-aminophenyl)-3-[(3-  
aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]- (9CI)  
MF C29 H28 N6 O2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L10 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Naphthalenecarboximidamide, 7-[[4-(4-aminophenyl)-3-[(3-  
aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]-,  
mono(trifluoroacetate) (9CI)  
MF C29 H28 N6 O2 . C2 H F3 O2

CM 1



CM 2

*trifluoroacetal  
salt*



ALL ANSWERS HAVE BEEN SCANNED

=> fil caplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	65.25	103.08	

FILE 'CAPLUS' ENTERED AT 19:03:36 ON 24 MAY 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2005 VOL 142 ISS 22  
 FILE LAST UPDATED: 23 May 2005 (20050523/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 4-aminophenyl(s)imidazolidin?  
 5106122 4  
 20235 AMINOPHENYL  
 7 AMINOPHENYLS

20240 AMINOPHENYL  
 (AMINOPHENYL OR AMINOPHENYLS)  
 6077 4-AMINOPHENYL  
 (4 (W) AMINOPHENYL)  
 10884 IMIDAZOLIDIN?  
 L11 15 4-AMINOPHENYL(S) IMIDAZOLIDIN?

=> d L11 ibib

L11 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:1154680 CAPLUS  
 DOCUMENT NUMBER: 142:93814  
 TITLE: Preparation of (indazolylphenyl),  
 (benzisoxazolylphenyl), (benzothiazolylphenyl) ureas  
 and related compounds as protein tyrosine kinase  
 inhibitors for treatment of cancer  
 INVENTOR(S): Dai, Yujia; Davidsen, Steven K.; Ericsson, Anna M.;  
 Hartandi, Kresna; Ji, Zhiqin; Michaelides, Michael R.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 224 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113304	A1	20041229	WO 2004-US16166	20040521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004235892	A1	20041125	US 2003-443254	20030522
US 2005020603	A1	20050127	US 2004-842292	20040510
PRIORITY APPLN. INFO.:			US 2003-443254	A 20030522
			US 2004-842292	A 20040510
			US 2003-472810P	P 20030522
OTHER SOURCE(S):	MARPAT 142:93814			
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> d L11 ibib abs 1-15

L11 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:1154680 CAPLUS  
 DOCUMENT NUMBER: 142:93814  
 TITLE: Preparation of (indazolylphenyl),  
 (benzisoxazolylphenyl), (benzothiazolylphenyl) ureas  
 and related compounds as protein tyrosine kinase  
 inhibitors for treatment of cancer  
 INVENTOR(S): Dai, Yujia; Davidsen, Steven K.; Ericsson, Anna M.;  
 Hartandi, Kresna; Ji, Zhiqin; Michaelides, Michael R.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 224 pp.

CODEN: PIXXD2

**DOCUMENT TYPE:**

Patent

## **LANGUAGE:**

English

FAMILY ACC. NUM. COUNT: 2

2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113304	A1	20041229	WO 2004-US16166	20040521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004235892	A1	20041125	US 2003-443254	20030522
US 2005020603	A1	20050127	US 2004-842292	20040510
PRIORITY APPLN. INFO.:				
US 2003-443254 A 20030522				
US 2004-842292 A 20040510				
US 2003-472810P P 20030522				

**OTHER SOURCE(S):**

MARPAT 142:93814

GT



AB The present invention also discloses methods of making the compds., compns. containing the compds., and methods of treatment using the compds. Title compds. I [wherein A = Ph or Ph fused to a 5- or 6-membered ring containing 1-2 N atoms; X = O, NR<sub>9</sub>, S; R<sub>1</sub>, R<sub>2</sub> = independently H, alkoxy(alkoxy), alkoxyalkyl, aryloxy(alkyl), halo(alkoxy), haloalkyl, heterocyclalkenyl, heterocyclalkoxy, heterocycl(oxy)alkyl, hydroxy(alkoxy), hydroxyalkyl, (un)substituted aminoalkoxy, , aminoalkenyl, aminoalkyl, carbamoylalkenyl, carbamoylalkyl; R<sub>3</sub>-R<sub>5</sub> = independently H, alkoxy, alkyl, halo(alkoxy), haloalkyl, LR<sub>6</sub>; with the proviso that at least 2 of R<sub>3</sub>-R<sub>5</sub> ≠ LR<sub>6</sub>; L = (CH<sub>2</sub>)<sub>m</sub>NR<sub>7</sub>CONR<sub>8</sub>(CH<sub>2</sub>)<sub>n</sub>, CH<sub>2</sub>CONR<sub>7</sub>; R<sub>6</sub> = (hetero)aryl; R<sub>7</sub>, R<sub>8</sub> = independently H, alkyl; R<sub>9</sub> = H, alkenyl, (alkoxy)alkyl, heterocyclalkyl, hydroxyalkyl, (un)substituted aminoalkyl; m, n = independently 0, 1; and therapeutically acceptable salts thereof] were prepared as protein tyrosine kinase inhibitors. For

example, the (indazolylphenyl)urea II was synthesized in three steps starting from 2-fluoro-6-iodobenzonitrile, hydrazine hydrate, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, and 1-isocyanato-3-methylbenzene. Compds. of the invention inhibited human KDR with IC<sub>50</sub> values ranging between about 0.003μM and about 40 μM. Thus, I and their pharmaceutical compns. are useful in the treatment of KDR mediated diseases, such as cancer (no data).

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1019784 CAPLUS

DOCUMENT NUMBER: 142:6528

TITLE: Preparation of (indazolylphenyl) and (benzisoxazolylphenyl) ureas and related compounds as protein tyrosine kinase inhibitors for treatment of cancer

INVENTOR(S): Dai, Yujia; Davidsen, Steven K.; Ericsson, Anna M.; Hartandi, Kresna; Ji, Zhiqin; Michaelides, Michael R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 49 pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004235892	A1	20041125	US 2003-443254	20030522
WO 2004113304	A1	20041229	WO 2004-US16166	20040521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-443254	A 20030522
			US 2004-842292	A 20040510
OTHER SOURCE(S): GI		MARPAT 142:6528		




AB Title compds. I [wherein A = Ph or Ph fused to a 5- or 6-membered ring containing 1-2 N atoms; X = O, NR 9; R1, R2 = independently H, alkoxy(alkoxy), alkoxyalkyl, aryloxy(alkyl), halo(alkoxy), haloalkyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocycl(oxy)alkyl, hydroxy(alkoxy), hydroxylalkyl, (un)substituted aminoalkoxy, , aminoalkenyl, aminoalkyl, carbamoylalkenyl, carbamoylalkyl; R3-R5 = independently H, alkoxy, alkyl, halo(alkoxy), haloalkyl, LR6; with the proviso that at least 2 of R3-R5  $\neq$  LR6; L =  $(\text{CH}_2)^m\text{NR}^7\text{CONR}^8(\text{CH}_2)^n$ ,  $\text{CH}_2\text{CONR}^7$ ; R6 = (hetero)aryl; R7, R8 = independently H, alkyl; R9 = H, alkenyl, (alkoxy)alkyl, heterocyclylalkyl, hydroxylalkyl, (un)substituted aminoalkyl; m, n = independently 0, 1; and therapeutically acceptable salts thereof] were prepared as protein tyrosine kinase inhibitors. For example, the (indazolylphenyl)urea II was synthesized in three steps starting from 2-fluoro-6-iodobenzonitrile, hydrazine hydrate, 4-(4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, and 1-isocyanato-3-methylbenzene. Compds. of the invention inhibited human KDR with IC<sub>50</sub> values ranging between about 0.003 $\mu\text{M}$  and about 40  $\mu\text{M}$ . Thus, I and their pharmaceutical compns. are useful in the treatment of KDR mediated diseases, such as cancer (no data).

L11 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:1016039 CAPLUS  
 DOCUMENT NUMBER: 142:6516  
 TITLE: Preparation of 2-thioxazolidones and related compounds for the treatment of thromboembolic illnesses  
 INVENTOR(S): Gerdes, Christoph; Perzborn, Elisabeth; Pohlmann, Jens; Roehrig, Susanne; Straub, Alexander; Thomas, Christian R.; Tuch, Arounarith; Schlemmer, Karl-Heinz  
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany  
 SOURCE: PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101557	A1	20041125	WO 2004-EP4836	20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

DE 10322469 A1 20041216 DE 2003-10322469 20030519  
 PRIORITY APPLN. INFO.: DE 2003-10322469 A 20030519  
 GI



AB Title compds. I [A = S(O)O, S(O<sub>2</sub>)O, S(O)NR<sub>5</sub>, etc.; M = (un)substituted aryl, pyridyl, pyrimidyl, etc.; R<sub>1</sub> = (un)substituted aryl, heteroaryl, heterocyclyl, etc.; R<sub>2</sub> = (un)substituted aryl, pyridyl, pyrimidyl, etc.; R<sub>3</sub> = H, alkyl; R<sub>4</sub> = H, (un)substituted alkoxy carbonyl, alkylaminocarbonyl, etc.; R<sub>5</sub> = H, alkyl; Y = O, S] and their pharmaceutically acceptable salts and formulations were prepared. For example, N,N'-thiocarbonyldiimidazole mediated cyclization of aminoalc. II, e.g., prepared from 1-(4-aminophenyl)imidazolidin-2-one and 5-chloro-N-(2S)-2-oxiranylmethyl)-2-thiophencarboxamide, afforded thioxazolidone III in 22% yield. Compds. I are claimed useful for the treatment of thromboembolic illnesses.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:335080 CAPLUS

DOCUMENT NUMBER: 138:337982

TITLE: Preparation of 2-carboxamidopyrroles as tyrosine kinase inhibitors

INVENTOR(S): Trotter, B. Wesley

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035619	A1	20030501	WO 2002-US33962	20021023
WO 2003035619	C1	20030703		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-343000P	P 20011025
OTHER SOURCE(S):		MARPAT 138:337982		
GI				



AB Title compds. I [wherein V = (cyclo)alkyl, aryl, heterocyclyl, or CO; W = a bond, cycloalkyl, aryl, or heterocyclyl; Ra and Rb = independently H, OR7, or (un)substituted alkyl, aryl, or heterocyclyl; R1 = independently H, halo, OR7, COR7, CO2R7, CON(R7)2, N(R7)2, SO2N(R5)2, or (un)substituted (cyclo)alkyl, aryl, or heterocyclyl; R2 = CO2R7, (CRb2)N(R7)2, (CRb2)nOR7, CON(R7)2, CONR7OR7, CONH(CRb2)qR7, CONR7NHCOR7, CONR7SO2OR7, CONH(CRb2)qCON(R7)2, or (un)substituted alkyl or aryl; R3 = H or (un)substituted alkyl, aralkyl, aryl, or heterocyclyl(alkyl); R4 = H, halo, OR7, COR7, CO2R7, CON(R7)2, N(R7)2, SO2N(R5)2, or (un)substituted (cyclo)alkyl, aryl, or heterocyclyl; R5 = independently H, or (un)substituted alkyl, aryl, or heterocyclyl; R6 = independently H, OR7, or (un)substituted alkyl, aralkyl, aryl, or heterocyclyl(alkyl); R7 = independently H or (un)substituted alkyl, aralkyl, aryl, or heterocyclyl(alkyl); n = independently 0-6; q = 0-5; or pharmaceutically acceptable salts or stereoisomers thereof] were prepared for inhibiting, modulating, and/or regulating signal transduction of both receptor type and non-receptor type tyrosine kinases. For example, N-[[5-(tert-

butoxycarbonyl)-3-(ethoxycarbonyl)-4-ethyl-1H-pyrrol-2-yl]methyl]-4-methoxybenzenaminium trifluoroacetate was converted to the acid using TFA (no data), and the product amidated with propylamine to give II•TFA. Compds. of the invention inhibited insulin-like growth factor I (IGF-1R) or insulin receptor (IR) kinase activity with IC<sub>50</sub> ≤ 100 μM. Thus, I are useful for the treatment of protein kinase related disorders, such as cancer, diabetes, autoimmune disorders, hyperproliferation disorders, aging, acromegaly, and Crohn's disease (no data).


REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:319488 CAPLUS  
 DOCUMENT NUMBER: 138:337988  
 TITLE: Novel 2-[(iminoethyl)amino]phenyl derivatives useful as inhibitors of NO synthase and lipid peroxidation, their preparation, their application as medicines, and pharmaceutical compositions containing them  
 INVENTOR(S): Chabrier De Lassauniere, Pierre Etienne; Auvin, Serge; Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah  
 PATENT ASSIGNEE(S): Societe de Conseils de Recherches et D'Applications scientifiques (S.C.R.A.S.), Fr.  
 SOURCE: U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of U.S. Ser. No. 882,264.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6335445	B1	20020101	US 1999-456205	19991207
US 2002007062	A1	20020117	US 2001-882264	20010615
US 6630461	B2	20031007		
US 2005043397	A1	20050224	US 2004-898916	20040726
PRIORITY APPLN. INFO.:			FR 1997-3528	A 19970324
			FR 1997-7701	A 19970620
			WO 1998-FR288	W 19980216

WO 1998-FR1250	W 19980615
US 1999-456205	A3 19991207
US 2001-882264	A2 20010615
US 1999-381749	A2 19990922
US 2002-191950	A3 20020709

OTHER SOURCE(S): MARPAT 138:337988  
GI



AB Title compds., e.g., N-[4-[[[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]methyl]phenyl]thiophene-2-carboximidamide (I) are prepared. The compds. are inhibitors of NO synthases, and are also antioxidants which inhibit lipid peroxidn. Approx. 70 examples are prepared. I had IC<sub>50</sub> for inhibiting rat neuronal NO synthase in vitro < 3.5 μM, and the IC<sub>50</sub> for inhibiting rat cerebral lipid peroxidn. in vitro is < 30 μM.

L11 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:805376 CAPLUS  
 DOCUMENT NUMBER: 138:238073  
 TITLE: Synthesis of 3-Ω-aminohydantoins  
 AUTHOR(S): Ryczek, Jozef  
 CORPORATE SOURCE: Department of Chemistry, Pedagogical University, Krakow, 30-084, Pol.  
 SOURCE: Journal of Heterocyclic Chemistry (2002), 39(5), 997-1000  
 CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 138:238073  
 AB Several 3-Ω-amino monosubstituted hydantoins have been obtained in the reaction of (isocyanato)acetic acid Et ester with the appropriate aliphatic or aromatic diamine. It was found, that the 3-(aminoaryl) monosubstituted hydantoins may be diazotized and their diazonium salts may be coupled and hydrolyzed without changes in the hydantoin ring. Compds. thus prepared included 3-[2-(dimethylamino)ethyl]-2,4-imidazolidinedione hydrochloride, 3-[2-(diethylamino)ethyl]-2,4-imidazolidinedione hydrochloride, 3-[3-(dimethylamino)propyl]-2,4-imidazolidinedione hydrochloride, 3-(4-aminophenyl)-2,4-imidazolidinedione hydrochloride, etc.


REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:793608 CAPLUS  
 DOCUMENT NUMBER: 137:310917  
 TITLE: Aromatic-substituted thiohydantoins, their preparation, and their use for treating diabetes, dyslipidemia, and obesity  
 INVENTOR(S): Boubia, Benaiessa; Chaput, Evelyne; Ou, Khan; Ratel, Philippe

PATENT ASSIGNEE(S): Laboratoires Fournier SA, Fr.  
SOURCE: PCT Int. Appl., 111 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081453	A1	20021017	WO 2002-FR1167	20020404
WO 2002081453	C1	20021114		
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
FR 2823209	A1	20021011	FR 2001-4552	20010404
FR 2823209	B1	20031212		
CA 2444024	AA	20021017	CA 2002-2444024	20020404
EP 1373219	A1	20040102	EP 2002-730333	20020404
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300485	A	20040216	EE 2003-485	20020404
BR 2002007910	A	20040803	BR 2002-7910	20020404
JP 2004525175	T2	20040819	JP 2002-579441	20020404
ZA 2003007372	A	20040922	ZA 2003-7372	20030922
US 2004116417	A1	20040617	US 2003-473032	20030926
NO 2003004430	A	20031006	NO 2003-4430	20031003
PRIORITY APPLN. INFO.:			FR 2001-4552	A 20010404
			WO 2002-FR1167	W 20020404

OTHER SOURCE(S): MARPAT 137:310917  
GI



AB The invention concerns compds. derived from 2-thiohydantoin, selected among compds. I [R1 = (un)substituted aromatic nucleus [substituents = halo, alkoxy, alkyl, alkylthio, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, OCH<sub>2</sub>O, or (un)substituted (homo)(thio)morpholine, (homo)piperidine, (homo)piperazine, etc.]; R2 = H, alkyl or cycloalkyl [optionally interrupted by O atoms(s)], haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, (un)substituted aromatic nucleus; R3 = H, alkyl; R4 = H, alkyl, OH; or R3R4 = CH<sub>2</sub>; provided that at least one of R1 and R2 is an aromatic nucleus bearing at least one (un)substituted (homo)(thio)morpholine, (homo)piperidine, (homo)piperazine, etc.] and their addition salts with acids, in particular their pharmaceutically acceptable salts. The invention also concerns methods for preparing I, pharmaceutical compns. containing them, and their use.

pharmacol. active substances, in particular for treating diabetes, diseases mediated by hyperglycemia, hypertriglyceridemia, dyslipidemia, or obesity. A total of 380 invention compds. and approx. 80 intermediates were prepared and characterized. When tested orally in mice at doses below 200 mg/kg, I reduced glucose levels by up to -73%, and reduced serum triglycerides by up to -56%, with favorable changes in lipid parameters (no specific data). For instance, 4-(4-morpholinyl)aniline reacted with Et 2-bromopropionate and NaOAc in ETOH to give 69% N-[4-(4-morpholinyl)phenyl]-DL-alanine Et ester. Cyclocondensation of this amino ester with 4-(isothiocyanato)anisole in refluxing toluene in the presence of AcOH gave 82.5% title compound II.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:658739 CAPLUS

DOCUMENT NUMBER: 136:5946

TITLE: Optically active antifungal azoles. XIII. Synthesis of stereoisomers and metabolites of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456)

AUTHOR(S): Ichikawa, Takashi; Yamada, Masami; Yamaguchi, Masashi; Kitazaki, Tomoyuki; Matsushita, Yoshihiro; Higashikawa, Keiko; Itoh, Katsumi

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(9), 1110-1119

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:5946

AB The title imidazolidinone (I) is a new antifungal agent selected as a candidate for clin. trials. The three stereoisomers (1S,2R)-I, (1S,2S)-I and (1R,2S)-I were prepared as authentic samples to determine the enantiomeric and diastereomeric purity of I as well as to compare their in vitro antifungal activity. Pharmacokinetic studies of I using rats identified the existence of metabolites in the liver homogenate. The structures of the major metabolites were assigned as C-4 hydroxylated and/or C-5 hydroxylated 2-imidazolidinone derivs. based on HPLC and LC/MS/MS analyses. These hydroxylated compds. were prepared by reduction of the corresponding imidazolidinediones and confirmed to be identical to the metabolites by HPLC. In vitro antifungal activities of the three stereoisomers and the synthesized metabolites were considerably weaker than I.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:137271 CAPLUS

DOCUMENT NUMBER: 132:194378

TITLE: Preparation of intermediates for triazole-containing imidazolone or imidazolidinone fungicides

INVENTOR(S): Ito, Katsuki; Kitazaki, Tomoyuki; Matsushita, Yoshihiro; Hosono, Hiroshi; Mitsudera, Hiroyuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000063364	A2	20000229	JP 1998-228003 JP 1998-228003	19980812 19980812
PRIORITY APPLN. INFO.:	OTHER SOURCE(S): CASREACT 132:194378; MARPAT 132:194378			
AB	ZCH <sub>2</sub> CAr(OH)CHR <sub>1</sub> N(CH <sub>2</sub> R <sub>3</sub> )CONHR <sub>2</sub> [I; Z = 1H-1,2,4-triazol-1-yl; Ar = (substituted) Ph; R <sub>1</sub> = H, lower alkyl; R <sub>2</sub> = (substituted) hydrocarbyl, (substituted) aromatic heterocyclyl; R <sub>3</sub> = CH <sub>2</sub> Y, (protected) CHO; Y = OH, halo], ZCH <sub>2</sub> CAr(OH)CHR <sub>1</sub> NRCH <sub>2</sub> R <sub>3</sub> ' [II; Z, Ar, R <sub>1</sub> = same as I; R = H, (substituted) benzyl; R <sub>3</sub> ' = CH <sub>2</sub> OH, (protected) CHO], their salts, and their preparation methods are claimed. I are converted into imidazolones by cyclization. (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-(1H-1,2,4-triazol-1-yl)methyloxirane was treated with 2,2-diethoxyethylamine and (i-PrO) <sub>4</sub> Ti in PROH under reflux for 24 h to give 73% (R,R)-II [Ar = 2,4-difluorophenyl, R <sub>1</sub> = Me, R = H, R <sub>3</sub> ' = CH(OEt) <sub>2</sub> ], which was amidated by Ph 4-(2,2,3,3-tetrafluoropropoxy)phenylcarbamate in ETOH under reflux for 18 h to give 69% (R,R)-I [Ar = 2,4-difluorophenyl, R <sub>1</sub> = Me, R <sub>2</sub> = C <sub>6</sub> H <sub>4</sub> OCH <sub>2</sub> CF <sub>2</sub> CHF <sub>2</sub> -p, R <sub>3</sub> = CH(OEt) <sub>2</sub> ].			

L11 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:516695 CAPLUS

DOCUMENT NUMBER: 122:315240

TITLE: Synthesis and characterization of soluble aromatic polyurea-amides from new N,N'-dimethyl-N,N'-bis(aminophenyl)ureas and aromatic dicarboxylic acid chlorides

AUTHOR(S): Park, Ki Hong; Tani, Takashi; Kakimoto, Masa-aki; Imai, Yoshio

CORPORATE SOURCE: Dep. Org. Polymeric Materials, Tokyo Inst. Technology, Tokyo, 152, Japan

SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (1995), 33(7), 1039-46  
CODEN: JPACEC; ISSN: 0887-624X

PUBLISHER: Wiley

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aromatic polyurea-polyamides having inherent viscosity 0.36-0.67 dL/g were prepared by low temperature solution polycondensation of N,N'-dimethyl-N,N'-bis(aminophenyl)ureas with various aromatic dicarboxylic acid chlorides. All the polymers were amorphous, and most were soluble in organic solvents such as N-methyl-2-pyrrolidone, AcNMe<sub>2</sub>, m-cresol, and pyridine. Some of the polymers could be solution cast into transparent, flexible films having good tensile properties. The Tg of the polyurea-polyamides were 244-272°C. The temperature of 10% weight loss under N was 430-480°.

L11 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:604136 CAPLUS

DOCUMENT NUMBER: 119:204136

TITLE: Polyimides containing cyclic urea groups

INVENTOR(S): Wolf, Peter; Kraeh, Claudia

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 6 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 4123245 A1 19930114 DE 1991-4123245 19910713  
 PRIORITY APPLN. INFO.: DE 1991-4123245 19910713  
 AB The title polyimides, with specified structures and good thermal stability, are prepared by polymerization of tetracarboxylic dianhydrides with aromatic diamines in aprotic, dipolar solvents followed by cyclization of the prepolymer. Adding 50 mmol 4,4'-oxydiphtalic anhydride to 50 mmol N,N'-bis(4-aminophenyl)2-imidazolidinone in 150 mL N-methylpyrrolidone with cooling, stirring for 5 h at room temperature, and dehydrating the polymer with Ac<sub>2</sub>O-pyridine at 70° gave a polyurea-polyimide with weight loss at 520° (TGA) 10%.

L11 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1989:497930 CAPLUS  
 DOCUMENT NUMBER: 111:97930  
 TITLE: Heat-resistant polyimide-polyether-polysulfones  
 INVENTOR(S): Oikawa, Hideaki; Kawashima, Saburo; Tamai, Masaji;  
 Ota, Masahiro; Yamaguchi, Teruhiro  
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01011131	A2	19890113	JP 1987-166915	19870706
PRIORITY APPLN. INFO.:			JP 1987-166915	19870706
GI				





AB The title polyimides I with improved adhesion are prepared Thus, 65 g 4-chlorophenyl sulfone and 110 g 2-(4-aminophenyl)-2-(4-hydroxyphenyl)propane were polymerized in 1,3-dimethyl-2-imidazolidinone in the presence of K<sub>2</sub>CO<sub>3</sub> then 66.885 g the polymer

was polymerized with 39.829 g 4,4'-(p-phenylenedioxy)diphthalic dianhydride in AcONMe<sub>2</sub> to give a polyamic acid solution. Then, the solution was cast on a glass plate and treated at 100–250° for 3 h to give a film having glass transition temperature 220° and 5% degradation temperature 547°, which was sandwiched with steel plates and pressed at 300° for 3 min to show tensile shear adhesion strength 320 kg/cm<sup>2</sup>.

L11 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1989:458878 CAPLUS  
 DOCUMENT NUMBER: 111:58878  
 TITLE: Polyimides and high-temperature adhesives thereof  
 INVENTOR(S): Tamai, Shoji; Ohta, Masahiro; Kawashima, Saburo;  
 Iiyama, Katsuaki; Oikawa, Hideaki; Yamaguchi, Akihiro  
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan  
 SOURCE: Eur. Pat. Appl., 14 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 297808	A1	19890104	EP 1988-305831	19880627
EP 297808	B1	19911211		
R: CH, DE, FR, GB, IT, LI, NL				
JP 01009226	A2	19890112	JP 1987-163940	19870702
JP 2535545	B2	19960918		
JP 01009227	A2	19890112	JP 1987-163941	19870702
US 4931531	A	19900605	US 1988-210789	19880624
AU 8818565	A1	19890105	AU 1988-18565	19880630
AU 586955	B2	19890727		
PRIORITY APPLN. INFO.:			JP 1987-163940	A 19870702
			JP 1987-163941	A 19870702

GI



I

AB Title polyimides with good chemical resistance are prepared from polyimides consisting of repeating units of I (R = tetravalent radical). Thus, a mixture of bis[4-[4-(4-aminophenoxy)phenoxy]phenyl] sulfone (II) [prepared from 0.75 mol 4-aminophenyl 4-hydroxyphenyl ether and 0.357 mol bis(4-chlorophenyl) sulfone with KOH, PhMe, and 1,3-dimethyl-2-imidazolidinone] 6.167, N,N-dimethylacetamide 47.3, and pyromellitic dianhydride 2.18 g was stirred for 20 h at room temperature in N to give a polymeric solution. A film (prepared by casting the solution in a glass

plate having thickness 35- $\mu$ m, tensile strength 14.2 kg/mm<sup>2</sup>, elongation 19.6%, and glass transition temperature 290°) was used to laminate 2-ply steel at 350° for 5 min to give a sample having shear strength 230 kg/mm<sup>2</sup> at room temperature and 200 kg/mm<sup>2</sup> at 250°.

L11 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:76324 CAPLUS

DOCUMENT NUMBER: 110:76324

TITLE: Polyimides, their preparation, high

temperature-resistant adhesives based on these polyimides, and bonding method using these adhesives

PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan

SOURCE: Neth. Appl., 18 pp.

CODEN: NAXXAN


DOCUMENT TYPE: Patent

LANGUAGE: Dutch

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 8700005	A	19880801	NL 1987-5	19870106
PRIORITY APPLN. INFO.:			NL 1987-5	19870106
GI				



AB The title polyimides are prepared by reacting a diamine I with a tetracarboxylic dianhydride in an organic solvent. Adhesives based on the polyimides are applied to a substrate, covered with an untreated surface of another substrate, and the assembly heated under pressure to a temperature above the glass transition temperature (Tg) of the polyimide to achieve bonding.

These compns. have excellent adhesive strength and stability at high temps. for long durations. A mixture of 4,4'-dichlorobenzophenone 57, 2-(4-hydroxyphenyl)-2-(4-aminophenyl)propane 110, 96% KOH 29.2 g, and 750 mL 1,3-dimethyl-2-imidazolidinone was heated at 160° for 8 h, cooled, filtered, and stripped of solvent. The residue was cooled, and 57 g of 35% HCl and 500 mL iso-PrOH were added and dissolved under heating, after which 50 g NaCl was added, and the mixture was cooled to sep. the crystals. The crystals were redissolved in 350 mL of 50% iso-PrOH under heating, 35 g NaCl was added, and the resulting crystals were filtered, neutralized with aqueous NaH4OH, water-washed, and dried to give 101.5 g of white, crystalline 99%-pure 4,4'-bis[4-(4-amino- $\alpha,\alpha$ -dimethylbenzyl)phenoxy]benzophenone (II). A mixture of II 31.6, AcNMe<sub>2</sub> 127.5, and pyromellitic dianhydride 10.9 g (added gradually) was reacted <30° under N for 20 h to give a polyamic acid having inherent viscosity 1.43 dL/g (35° in 0.5% AcNMe<sub>2</sub>). Films of the imide had Tg 219°. A film of the polymer was placed between cold-rolled steel plates, preheated to 130°, and the assembly heated at 340° and 20 kg/cm<sup>2</sup> for 5 min to give a laminate having shear strength 240 and 140 kg/cm<sup>2</sup> at room temperature and 240°, resp.

L11 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1987:176951 CAPLUS  
DOCUMENT NUMBER: 106:176951  
TITLE: Strictly alternating copolymers containing parabanic acid and amide or imide moieties  
AUTHOR(S): Bennett, Cynthia; Heitz, Walter  
CORPORATE SOURCE: Fachber. Phys. Chem., Philipps-Univ. Marburg, Marburg,  
D-3550, Fed. Rep. Ger.  
SOURCE: Makromolekulare Chemie (1987), 188(3), 475-93  
CODEN: MACEAK; ISSN: 0025-116X  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB 1,3-Bis(**4-aminophenyl**)imidazolidinetrione  
dihydrochloride (I) [107701-60-0] was synthesized and used as starting material for the synthesis of strictly alternating copolymers with diacid chlorides. Fully aromatic copolymers containing parabanic acid and amide moieties exhibited high glass temps. and good thermal stability. Meltable copolymers with parabanic acid and amide moieties could be obtained by introducing flexible aliphatic spacers. The use of an unusually short, but sym. branched spacer was particularly effective. A strictly alternating, thermally stable polyimide [107982-10-5] was synthesized from I and pyromellitic dianhydride [89-32-7]. By using a trimethylsilyl ester, the imidization temperature could be lowered by 100°.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	48.77	151.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.95	-10.95

STN INTERNATIONAL LOGOFF AT 19:06:42 ON 24 MAY 2005

5/24/05 10/668,920

FILE 'HOME' ENTERED AT 19:46:42 ON 24 MAY 2005

=> fil reg  
COST IN U.S. DOLLARS  
  
FULL ESTIMATED COST

19:46:42 ON 24 MAY 2005

1) Structure search building out from "selected compound"  
SINCE FILE TOTAL  
ENTRY SESSION  
0.84 0.84  
to include all compounds in Class 3?

FILE 'REGISTRY' ENTERED AT 19:49:18 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with DC are from the ZINC15

Property values tagged with ~~Info~~ from the zic were provided by InfoChile.

Property values tagged with ~~NC~~ are from the ZINC15INITI data file provided by InfoChem.

Property values tagged with ~~IC~~ are from the ZIC/INITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6  
DICTIONARY FILE UPDATES: 23 MAY 2005 HIGHEST RN 850992-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

2 hits:  
s. this app  
ch. ref.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10668920a.str



```

chain nodes :
11 12 13 19 20 21 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 22 23 24 25 26 27 28 29
30 31 32 33
chain bonds :
2-21 9-12 11-12 12-13 14-21 15-20 16-26 17-34 18-19 33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-18 15-16 16-17
17-18 22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31 31-32
32-33
exact/norm bonds :
11-12 12-13 14-15 14-18 14-21 15-16 15-20 16-17 17-18 17-34 18-19
exact bonds :
2-21 9-12 16-26 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 22-23 22-27 23-24 24-25
25-26 26-27 28-29 28-33 29-30 30-31 31-32 32-33

```

Match level :


```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS

```

L1 STRUCTURE UPLOADED

=> d  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1  
SAMPLE SEARCH INITIATED 19:49:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS  
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 11 TO 389  
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s L1 full  
FULL SEARCH INITIATED 19:49:44 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 203 TO ITERATE

100.0% PROCESSED 203 ITERATIONS  
SEARCH TIME: 00.00.01

85 ANSWERS

L3 85 SEA SSS FUL L1  
~~fil caplus~~  
COST IN U.S. DOLLARS  
~~FULL ESTIMATED COST~~

SINCE FILE ENTRY	TOTAL SESSION
161.33	162.17

FILE 'CAPLUS' ENTERED AT 19:49:48 ON 24 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2005 VOL 142 ISS 22  
FILE LAST UPDATED: 23 May 2005 (20050523/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3  
L4 2 L3  
=> d L4-1-2 ibib abs hitstr


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:513339 CAPLUS  
DOCUMENT NUMBER: 141:54344  
TITLE: Preparation of imidazolidinediones as factor VIIa/tissue factor inhibitors for the treatment of thrombosis.  
INVENTOR(S): Arnaiz, Damian O.; Chou, Yuo-Ling; Griedel, Brian D.; Mohan, Raju; Shaw, Kenneth J.

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany  
 SOURCE: U.S. Pat. Appl. Publ., 18 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122073	A1	20040624	US 2003-668920	20030923
PRIORITY APPLN. INFO.:			US 2002-413067P	P 20020924
OTHER SOURCE(S):	MARPAT 141:54344			
GI				



I



II

AB Tilte compds. I [R1 = alkyl, alkenyl, alkynyl, etc.; R2, R3 = alkyl, alkenyl, alkynyl, etc.; A = (un)substituted alkylene, alkylidene, alkylidyne, etc.; B = aryl, heteroaryl; R4 = amidine, carboxyamidine, hydroxyamidine, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, imidazolidinedione II trifluoracetic acid salt was prepared from 5-methyl-5-phenylhydantoin in 3-steps. In factor VIIa/tissue factor inhibition assays, 90-examples of compds. I exhibited ki values of about 5 $\mu$ M or less (sic). Compds. I are claimed useful as anticoagulant and antithrombotic agents.

IT 708264-37-3P 708264-39-5P 708264-41-9P  
 708264-43-1P 708264-49-7P 708264-51-1P  
 708264-61-3P 708264-63-5P 708264-65-7P  
 708264-71-5P 708264-73-7P 708264-75-9P  
 708264-79-3P 708264-81-7P 708264-83-9P  
 708264-85-1P 708264-87-3P 708264-89-5P  
 708264-91-9P 708264-93-1P 708265-01-4P  
 708265-03-6P 708265-11-6P 708265-13-8P  
 708265-15-0P 708265-19-4P 708265-21-8P  
 708265-25-2P 708265-27-4P 708265-29-6P  
 708265-65-0P 708265-67-2P 708265-69-4P  
 708265-73-0P 708265-75-2P 708265-81-0P  
 708265-83-2P 708265-91-2P 708265-95-6P  
 708265-97-8P 708265-99-0P 708266-01-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of imidazolidinediones as anticoagulant and antithrombotic  
agents.)


RN 708264-37-3 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[3-[[4-(aminoiminomethyl)phenyl]methyl]-4-  
methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]methyl]-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-36-2


CMF C30 H28 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-39-5 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[4-methyl-2,5-dioxo-4-phenyl-3-  
(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 708264-38-4


CMF C29 H26 N4 O2



CM 2

a


CRN 76-05-1  
CMF C2 H F3 O2



RN 708264-41-9 CAPLUS  
CN Benzoic acid, 4-[{3-[7-(aminoiminomethyl)-2-naphthalenyl]methyl}-5-methyl-2,4-dioxo-5-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708264-40-8  
CMF C30 H26 N4 O4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708264-43-1 CAPLUS  
CN Benzoic acid, 3-[{3-[7-(aminoiminomethyl)-2-naphthalenyl]methyl}-5-methyl-2,4-dioxo-5-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1


CRN 708264-42-0  
CMF C30 H26 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-49-7 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[4-methyl-3-[(3-nitrophenyl)methyl]-2,5-dioxo-4-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 708264-48-6


CMF C29 H25 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-51-1 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[3-[(3-aminophenyl)methyl]-4-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

Q


CM 1

CRN 708264-50-0  
CMF C29 H27 N5 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708264-61-3 CAPLUS

CN Benzoic acid, 3-[[3-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-5-methyl-2,4-dioxo-5-phenyl-1-imidazolidinylmethyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708264-60-2  
CMF C31 H28 N4 O4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708264-63-5 CAPLUS  
CN Benzamide, 4-[[3-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-5-methyl-2,4-dioxo-5-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708264-62-4  
CMF C30 H27 N5 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708264-65-7 CAPLUS  
CN Benzamide, 3-[[3-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-5-methyl-2,4-dioxo-5-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708264-64-6  
CMF C30 H27 N5 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708264-71-5 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[3-[[4-(dimethylamino)phenyl]methyl]-2,5-dioxo-4,4-diphenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-70-4


CMF C36 H33 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-73-7 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[3-[[5-(dimethylamino)-2-methoxyphenyl]methyl]-2,5-dioxo-4,4-diphenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708264-72-6

CMF C37 H35 N5 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708264-75-9 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[3-[[3-(dimethylamino)phenyl]methyl]-2,5-dioxo-4,4-diphenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708264-74-8  
CMF C36 H33 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708264-79-3 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[4-[4-(1H-imidazol-1-yl)phenyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708264-78-2  
CMF C32 H28 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-81-7 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[3-[(3-aminophenyl)methyl]-4-[4-(1H-imidazol-1-yl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-80-6


CMF C32 H29 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-83-9 CAPLUS

CN Benzoic acid, 3-[[3-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-5-[4-(1H-imidazol-1-yl)phenyl]-5-methyl-2,4-dioxo-1-imidazolidinyl]methyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-82-8


CMF C34 H30 N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-85-1 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[3-[(3-aminophenyl)methyl]-4-(1,3-benzodioxol-5-yl)-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-84-0


CMF C30 H27 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-87-3 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[4-(1,3-benzodioxol-5-yl)-4-methyl-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-86-2


CMF C30 H26 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-89-5 CAPLUS

CN Benzoic acid, 3-[(3-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-5-(1,3-benzodioxol-5-yl)-5-methyl-2,4-dioxo-1-imidazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708264-88-4


CMF C31 H26 N4 06



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708264-91-9 CAPLUS

CN Acetic acid, [4-[1-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708264-90-8

CMF C31 H28 N4 O5



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 708264-93-1 CAPLUS  
 CN Acetic acid, [4-[1-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinylphenoxy]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708264-92-0  
 CMF C32 H30 N4 O5



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 708265-01-4 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[4-methyl-4-[4-[methyl(phenylmethyl)amino]phenyl]-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708265-00-3


CMF C37 H35 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708265-03-6 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[4-(4-aminophenyl)-4-methyl-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708265-02-5

CMF C29 H27 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-11-6 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[3-[(4-aminophenyl)methyl]-4-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708265-10-5  
CMF C29 H27 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-13-8 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[3-[(2-aminophenyl)methyl]-4-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708265-12-7  
CMF C29 H27 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-15-0 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[4-methyl-3-[(2-nitrophenyl)methyl]-2,5-dioxo-4-phenyl-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708265-14-9  
CMF C29 H25 N5 O4



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708265-19-4 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[2,5-dioxo-4-phenyl-3,4-bis(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708265-18-3


CMF C35 H30 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708265-21-8 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[2,5-dioxo-4-phenyl-4-(2-phenylethyl)-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708265-20-7

CMF C36 H32 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-25-2 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[4-[4-(dimethylamino)phenyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-24-1  
CMF C31 H31 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-27-4 CAPLUS  
CN 2-Naphthalenecarboximidamide, 7-[[4-methyl-2,5-dioxo-3-(phenylmethyl)-4-[4-[(phenylmethyl)amino]phenyl]-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-26-3  
CMF C36 H33 N5 O2



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 708265-29-6 CAPLUS  
 CN 2-Naphthalenecarboximidamide, 7-[[4-(4-aminophenyl)-3-(4-aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinylmethyl]methyltrifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 708265-28-5  
 CMF C29 H28 N6 O2



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 708265-65-0 CAPLUS  
 CN Benzoic acid, 4-[1-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-64-9  
 CMF C30 H26 N4 O4



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 708265-67-2 CAPLUS  
 CN Benzoic acid, 3-[1-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-66-1  
 CMF C30 H26 N4 O4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-69-4 CAPLUS  
CN Benzamide, 4-[1-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinyl-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708265-68-3  
CMF C30 H27 N5 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708265-73-0 CAPLUS

CN Benzamide, 3-[1-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708265-72-9


CMF C30 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708265-75-2 CAPLUS

CN Benzoic acid, 4-[1-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-4-imidazolidinyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708265-74-1

CMF C31 H28 N4 O4



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708265-81-0 CAPLUS

CN 4-Imidazolidineacetic acid, 1-[(7-(aminoininomethyl)-2-naphthalenyl)methyl]-2,5-dioxo-4-phenyl-3-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-80-9  
CMF C30 H26 N4 O4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-83-2 CAPLUS  
CN 4-Imidazolidinepropanamide, 1-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-2,5-dioxo-4-phenyl-3-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-82-1  
CMF C31 H29 N5 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 708265-91-2 CAPLUS  
CN 4-Imidazolidineacetic acid, 1-[[7-(aminoiminomethyl)-2-naphthalenyl]methyl]-2,5-dioxo-4-phenyl-3-(phenylmethyl)-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-90-1  
CMF C31 H28 N4 O4



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708265-95-6 CAPLUS

CN 4-Imidazolidinepropanoic acid, 1-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-2,5-dioxo-4-phenyl-3-(phenylmethyl)-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 708265-94-5


CMF C32 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 708265-97-8 CAPLUS

CN 4-Imidazolidineacetamide, 1-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-2,5-dioxo-4-phenyl-3-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 708265-96-7

CMF C30 H27 N5 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708265-99-0 CAPLUS

CN 4-Imidazolidinepropanoic acid, 1-[(7-(aminoiminomethyl)-2-naphthalenyl)methyl]-2,5-dioxo-4-phenyl-3-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 708265-98-9  
CMF C31 H28 N4 04



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 708266-01-7 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[[4-methyl-4-(2-naphthalenyl)-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]methyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 708266-00-6  
CMF C33 H28 N4 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:869482 CAPLUS  
 DOCUMENT NUMBER: 137:365551  
 TITLE: Direct measurement of coagulation factor VIIa activity in plasma and application to screening of Factor VIIa inhibitors  
 INVENTOR(S): Chi, Liguo; Leadley, Robert Joseph, Jr.; Peng, Yun-Wen  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002168700	A1	20021114	US 2002-141396	20020508
US 6773896	B2	20040810		
EP 1260817	A2	20021127	EP 2002-9326	20020502
EP 1260817	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2385212	AA	20021108	CA 2002-2385212	20020506
JP 2002360297	A2	20021217	JP 2002-131432	20020507
PRIORITY APPLN. INFO.:			US 2001-289539P	P 20010508
AB	The present invention generally provides a method of measuring the biol. activity of coagulation factor VIIa (Factor VIIa). Specifically, the present invention provides a method for directly measuring the activity of Factor VIIa in a plasma sample. The method of the present invention includes the steps of combining a quantity of a plasma sample with acetonitrile, drying the plasma sample, and combining the dried plasma with a solution containing a buffer, Factor VIIa, and a detectable Factor VIIa substrate (preferably chromogenic substrate). More specifically, the present invention provides a method for utilizing Factor VIIa activity as a bio-marker to monitor Factor VIIa inhibition to screen compds. which are able to inhibit the biol. activity of Factor VIIa. Plasma concentration of			

Factor VIIa inhibitors can be estimated based on the Factor VIIa assay of the invention in various concns. of plasma.


IT 475090-18-7, PD 313049

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Factor VIIa inhibitor; direct measurement of coagulation factor VIIa activity in plasma and application to screening of Factor VIIa inhibitors)

RN 475090-18-7 CAPLUS

CN 2-Naphthalenecarboximidamide, 7-[(4R)-4-(4-aminophenyl)-3-[(3-aminophenyl)methyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.68	173.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

STN INTERNATIONAL LOGOFF AT 19:52:20 ON 24 MAY 2005